YFYuri Matteo Falzone

Yuri Matteo Falzone

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yuri Matteo Falzone has a total of 369 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cranial Neuropathies—Easy to See, Hard to Diagnose

    by Adele Ratti, Luca Bosco, Christian Laurini, Luca Angelini, Benedetta Sorrenti, Massimo Filippi, Stefano Carlo Previtali, Yuri Matteo Falzone

    Purpose of ReviewCranial neuropathies are a frequent reason for neurologic consultation, yet they remain diagnostically challenging because of a broad etiologic spectrum and overlapping clinical pr...

  • Electrodiagnostic Classification of Sensory Neuropathies: Severity Clusters and Clinical Correlates

    by Luca Bosco, Christian Laurini, Luca Angelini, Marco Bosco, Adele Ratti, Paride Schito, Tommaso Russo, Benedetta Sorrenti, Camilla Mirella Maria Strano, Calogera Butera, et al.

    Introduction/Aims: Grading sensory neuropathy severity on nerve conduction studies (NCS) is operator dependent, which limits comparisons across patients, laboratories, and studies. We aimed to develop an objective severity classification to standardize NCS reporting and support clinical decision‐making. Methods: We retrospectively analyzed NCS performed at IRCCS San Raffaele Hospital (2018–2024), extracted with a validated parser. Adult studies with sensory involvement were selected using sural sensory nerve action potential ( SNAP ) amplitude thresholds after excluding motor abnormalities. Hierarchical clustering combined normalized sural and “best” upper‐limb ( UL ) SNAP amplitudes with binary indicators for absent responses. Classes were ordered by an NCS severity index and validated against clinical scales. Results: Among 15,744 consecutive examinations, 308 met inclusion criteria. Three well‐separated NCS severity classes emerged: mild (reduced but present sural and present UL SNAPs ), moderate (absent sural, present UL SNAPs ), and severe (absent sural and UL SNAPs ). Clinical severity increased monotonically across classes. Patients in the severe class had younger age at symptom onset than those in mild‐moderate classes and were more disabled (modified Rankin scale ≥ 2: 50.0% in severe vs 30.4% in moderate vs 16.2% in mild). The severe class was enriched in immune/paraneoplastic (12.5%) and genetic (40.6%) causes. Discussion: By stratifying patients based on SNAP amplitudes, we identified a differential etiologic enrichment rather than a continuum of disease progression. Severe electrophysiology with motor sparing should prompt RFC1 testing and immune/paraneoplastic work‐up, whereas mild to moderate abnormalities should lead to assessment for diabetes and toxic or nutritional exposures.

  • Patient-Reported Complications and Outcomes of General, Central Neuraxial, and Peripheral Regional Anesthesia in Charcot-Marie-Tooth Disease

    by Alessandro Bertini, Marco Gemma, Fiore Manganelli, Stefano Carlo Previtali, Gian Maria Fabrizi, Angelo Schenone, Lucio Santoro, Matteo Tagliapietra, Tiziana Cavallaro, Marina Grandis, et al.

  • Open Access

    Refining Electrophysiological Criteria in CIDP and MMN : Toward a Unified Definition of Motor Conduction Block and Proximal Temporal Dispersion

    by Chiara Gallo, Carla Fasano, Angelo Fonseca, Yuri Falzone, Dario Cocito, Fiore Manganelli, Sabrina Matà, Giuseppe Cosentino, Vincenzo Di Stefano, Massimiliano Filosto, et al.

    Background: The definition of motor conduction block (CB) and proximal temporal dispersion (TD) for the diagnosis of CIDP and MMN remains debated, particularly regarding whether CB should be based on amplitude or area reduction, and whether proximal TD is best assessed using negative peak or total CMAP duration. Methods: Nerve conduction waveforms from 106 CIDP, 87 MMN, and 234 controls were analyzed. Motor CB was defined by ≥ 30%, ≥ 40%, or ≥ 50% amplitude or area reduction. Proximal TD was defined as a ≥ 30% increase in negative peak duration, total CMAP duration, or either criterion. Sensitivity, specificity, and inter‐rater reliability were analyzed. Results: Across both CIDP and MMN, a ≥ 30% reduction in CMAP amplitude showed diagnostic performance comparable to area‐based CB definitions and outperformed higher cutoff values. Requiring CB in multiple nerves increased specificity but reduced sensitivity. For proximal TD, negative peak duration was the most robust single parameter. Total CMAP duration identified additional abnormalities and, when combined with negative peak duration, improved diagnostic sensitivity in both disorders while maintaining high specificity. Total CMAP duration demonstrated good inter‐rater agreement at the patient level. CMAP morphology showed substantial overlap between CIDP and MMN and limited discriminatory value. Conclusions: A ≥ 30% reduction in CMAP amplitude can be used as a universal definition of motor CB in both CIDP and MMN, providing diagnostic performance comparable to area‐based criteria with greater simplicity. In addition, proximal TD assessed using total CMAP duration may represent a complementary electrophysiological criterion in both disorders.

  • Open Access

    Expanding the AFG3L2 Spectrum

    by Alessandra Rocco, Christian Laurini, Yuri Matteo Falzone, Silvia Calzavara, Ubaldo Del Carro, Stefano Carlo Previtali, Francesca Maltecca

    The AFG3L2 gene encodes a mitochondrial AAA-protease involved in inner mitochondrial membrane (IMM) proteostasis. Heterozygous variants in the AFG3L2 proteolytic domain cause Spinocerebellar Ataxia type 28, heterozygous variants in the AFG3L2 ATPase domain cause Optic Atrophy type 12, while biallelic variants lead to recessive Spastic Ataxia type 5. In this study, we aimed to investigate the link between AFG3L2 haploinsufficiency and Charcot-Marie-Tooth (CMT) phenotypes. We performed clinical evaluation, genetic analyses, electrophysiology, and functional studies in 1 patient's fibroblasts. In this study, we report a patient presenting with progressive symmetric distal muscle atrophy, weakness, pes cavus, and sensory deficits at lower limbs, in the absence of cerebellar or pyramidal signs. Electrophysiologic studies confirmed axonal sensorimotor neuropathy. After excluding common CMT-related genes, clinical exome sequencing revealed a heterozygous truncating variant in AFG3L2 [NM_006793.3:c.121C > T; p.(Arg41*)]. In patient's fibroblasts, we observed ∼50% reduction in AFG3L2 protein levels, which is sufficient to hyperactivate the stress-sensitive IMM protease OMA1. Consequently, we detected increased OPA1 processing, mitochondrial shortening, and activation of the integrated stress response. These findings suggest that AFG3L2 haploinsufficiency can underlie axonal CMT, expanding the clinical spectrum of AFG3L2-related diseases and emphasizing its potential inclusion in CMT diagnostic panels.

  • Open Access

    Spectrum of dominant Charcot-Marie-Tooth disease due to SLC12A6 variants

    by Christopher J Record, Tiffany Grider, Adriana P Rebelo, Christian Laurini, Mariola Skorupinska, Matt C Danzi, Roy Poh, Pedro J Tomaselli, Rodrigo S Frezatti, Natalia Dominik, et al.

    Background: Heterozygous variants in SLC12A6 have recently been shown to cause dominant Charcot-Marie-Tooth disease (CMT). We aim to characterise the phenotype of patients with previously reported and novel heterozygous variants in the gene and understand any genotype-phenotype correlation. Methods: Patients were clinically and genetically assessed in sites from Europe, Australia, Brazil and the USA. All patients underwent whole exome or whole genome sequencing. Variants were classified using American College of Medical Genetics and Genomics criteria. Results: Twenty-three individuals from 13 families carried nine variants classified either as pathogenic/likely pathogenic or variants of uncertain significance segregating in multiple family members, including five novel variants. Forty-eight percent (11/23) were male with a mean age of disease onset of 15.7 years (range 1–45 years). Clinical phenotype varied dramatically with genotype; Arg207His and Ser647Pro caused a severe childhood-onset, sensory and motor, conduction-slowing neuropathy, whereas Gly552Asp caused a mild, adult-onset, sensory-predominant neuropathy, Thr991Ala an infantile-onset motor neuropathy, and the Met282Lys/Gly286Cys locus a complex, axonal neuropathy. Conclusions: Heterozygous variants in SLC12A6 can cause CMT of all clinical phenotypes, severity and age of onset, depending on the genotype. Such phenotypic diversity has not been described for any other CMT gene, and more work is needed to understand disease mechanisms to guide future therapeutic options.


  • Open Access

    Phenotype-Genotype Correlations in Early-Onset Myelin Protein Zero–Related Neuropathies

    by Christian Laurini, Federica Rachele Danti, Massimo Russo, Stefano Tozza, Sara Massucco, Alessandro Bertini, Chiara Pisciotta, Federica D'ARma, Luca Gentile, Yuri Matteo Falzone, et al.

    Myelin protein zero (MPZ)–related neuropathies include demyelinating CMT1B and later-onset axonal forms (CMT2I/J). CMT1B pathogenic variants act through gain-of-function, destabilizing MPZ and activating the unfolded protein response (UPR), or loss-of-function, disrupting MPZ homomeric interactions in myelin. This study investigates early-onset (s = 0.56; p < 0.001), suggesting disease progression in this cohort. Destabilizing variants were associated with earlier onset (p < 0.001), upper limb involvement (p < 0.001), impaired ambulation (p < 0.01), scoliosis (p < 0.01), and faster progression as measured by CMTES/age (0.24 vs 0.11 CMTES/year). After excluding the c.245A>C, p.Y82S outlier (highly destabilizing but not UPR-activating), ∆∆G values showed significant correlations with age at onset (rs = 0.54, p = 0.030), CMTES (rs = −0.82, p < 0.001), and progression (rs = −0.60, p = 0.032). Stratification of MPZ variants into destabilizing and non-destabilizing is crucial for predicting severity and prognosis and tailoring therapeutic strategies. This approach has significant implications for upcoming UPR-modulating treatments and underscores the necessity of integrating molecular and clinical insights for optimal patient care.


  • Open Access

    Understanding Long-Term Survival in ALS: A Cohort Study on Subject Characteristics and Prognostic Factors

    by Elisabetta Pupillo, Elisa Bianchi, Maurizio Angelo Leone, Massimo Corbo, Massimiliano Filosto, Alessandro Padovani, Barbara Risi, Marcella Vedovello, Valentina Dell’era, Federica Cerri, et al.

    Background: Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease with variable clinical progression. While median survival is 2–4 years, 5–15% of individuals survive for longer. Methods: We conducted a retrospective, observational study using a population-based ALS register in Lombardy, Italy, to identify the clinical characteristics of long-term ALS survivors (≥10 years). Incident cases included in two periods (1998–2002 and 2008–2012) were considered. Results: A total of 828 ALS cases were included. Median survival for the entire cohort was 2.2 years (IQR 1.1–4.4). However, long-term survival was observed in 7% of individuals at 10 years, and 3% at 15 years. Long-survivors had a median survival of 13.4 years, significantly longer than the 1.9 years of non-long-survivors (IQR 1.0–3.6). Long-survivors were younger at disease onset and diagnosis, had longer diagnostic delay, and were more likely to have had a spinal onset. The cohort also showed a higher proportion of males among long-term survivors (75% vs. 59%). No significant difference in survival was observed between the two examined periods. Conclusions: Our findings suggest that long-term ALS survival is likely influenced by a complex interplay of clinical, genetic, and environmental factors, along with the intrinsic rate of motor neuron degeneration.


  • Clinical, Histopathologic, and Genetic Features of Patients With Myofibrillar and Distal Myopathies

    by Sara Bortolani, Marco Savarese, Gaetano Vattemi, Silvia Bonanno, Yuri M. Falzone, Alessia Pugliese, Guido Primiano, Cristina Sancricca, Diego Lopergolo, Giulia Greco, et al.

    The diagnostic process for myofibrillar myopathies (MFM) and distal myopathies (DM) is particularly complex because of the large number of causative genes, the existence of still molecularly undefined disease entities, and the overlapping features between the 2 categories. This study aimed to characterize a large cohort of patients affected by MFM and DM and identify the most important diagnostic and prognostic aspects of these diseases. Patients with either a myopathological diagnosis of MFM or a clinical diagnosis of DM were included in this retrospective multicentric national study. Demographic, genetic, clinical, and histopathologic data of anonymized patients were collected from the neuromuscular centers of the Italian Association of Myology network. Data regarding 132 patients with MFM (mean age 57.0 ± 15.8 years, 49% female) and 298 patients with DM (mean age 50.7 ± 15.9 years, 40% female) were gathered from 20 neuromuscular centers. 69 patients fulfilled the criteria for both groups (distal myopathies with myofibrillar pathology, DM-MP). Molecular confirmation was achieved in 63% of the patients. Fifty-two percent of the patients with MFM carried pathogenic variants in either DES (n = 30), MYOT (n = 20), or DNAJB6 (n = 18), which were also the most frequent disease-causing genes in DM-MP, while GNE (n = 44) and MYH7 (n = 23) were the genes most commonly carrying pathogenic variants in DM. The mean age at onset varied from MYH7 and DYSF to 59 years in patients with myotilinopathies. Cardiac involvement was reported in 29% of patients with MFM and 16% of patients with DM, with DES and MYH7 variants significantly associated with the development of cardiomyopathy. Respiratory impairment was more prevalent in patients with TTN and DES variants and rare in other disorders such as GNE myopathy and dysferlinopathies, which were instead associated, together with DNAJB6-related and PLIN4-related myopathies, with the risk of losing ambulation during the disease course. The Italian cohort of patients with MFM and DM recapitulates the phenotypic heterogeneity and the partial overlap between the 2 groups. However, in relative contrast to the encountered phenotypic variability, only 5 genes accounted for most of the molecular diagnoses. Specific genetic entities are associated with significantly increased risk of developing cardiorespiratory complications or loss of ambulation, which has relevant prognostic implications.


  • Open Access

    Phenotypic spectrum of myelin protein zero-related neuropathies: a large cohort study from five mutation clusters across Italy

    by Alessandro Bertini, Luca Gentile, Tiziana Cavallaro, Stefano Tozza, Paola Saveri, Massimo Russo, Sara Massucco, Yuri Matteo Falzone, Emilia Bellone, Federica Taioli, et al.

    Background: We aimed to investigate the clinical features of a large cohort of patients with myelin protein zero (MPZ)-related neuropathy, focusing on the five main mutation clusters across Italy.Methods: We retrospectively gathered a minimal data set of clinical information in a series of patients with these frequent mutations recruited among Italian Charcot-Marie-Tooth (CMT) registry centres, including disease onset/severity (CMTES-CMT Examination Score), motor/sensory symptoms and use of orthotics/aids.Results: We collected data from 186 patients: 60 had the p.Ser78Leu variant (‘classical’ CMT1B; from Eastern Sicily), 42 the p.Pro70Ser (CMT2I; mainly from Lombardy), 38 the p.Thr124Met (CMT2J; from Veneto), 25 the p.Ser44Phe (CMT2I; from Sardinia) and 21 the p.Asp104ThrfsX13 (mild CMT1B; from Apulia) mutation. Disease severity (CMTES) was higher (pMPZ(and late-onset CMT2) cohort ever collected, reporting clinical features and disease progression of 186 patients from five different clusters across Italy. Our findings corroborate the importance of differentiating between ‘classical’ childhood-onset demyelinating, late-onset axonal and mildMPZ-related neuropathy, characterised by different pathomechanisms, in view of different therapeutic targets.